Synergistic extra and intracellular recognition of F. tularensis

土拉弗朗西斯胞外和胞内的协同识别

基本信息

  • 批准号:
    8110762
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-16 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Surface-expressed Toll-like receptors (TLRs) and a newly described class of cytosolic pattern recognition receptors (PRRs), members of the Nod-like receptor (NLR) family, play a major role in innate host defense against the intracellular pathogen Francisella tularensis, a category A biothreat agent. Recently it was shown that F.tularensis triggers TLR2 signaling in immune cells and that mutation of this PRR is associated with greater susceptibility to infection. Similarly, signaling through apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), an NLR adaptor molecule, and subsequent caspase-1 activation were shown to be essential for eliciting protective immunity to F. tularensis infection. One intriguing question which remains unanswered is the precise relationship between the TLR and NLR signaling pathways and whether activation of NLRs in response to F. tularensis occurs downstream of TLRs or proceeds independent of TLR signaling. Furthermore, the specific component(s) of F. tularensis that triggers the downstream signaling events and the receptor(s) of the NLR pathways are not known. This proposal seeks to address these issues by testing the hypothesis that integration of signals transduced via the TLR2 and NLR pathway is required for the optimal development of innate immune responses to F. tularensis infection via the following Specific Aims: 1) Identify the F. tularensis SchuS4 component(s) activating the NLR pathway and evaluate the role of select NLRs in mediating the pro-inflammatory responses to F. tularensis. 2) Establish the key sites of integration between the TLR2 and NLR signaling pathways in response to F. tularensis SchuS4. This proposal will study the cell biology of signal integration between key components of innate immunity and how these processes at the cellular level contribute to the host's ability to resist microbial challenge. Defining the molecular mechanism(s) of innate immunity will be an essential first step towards development of immunotherapeutic, as well as effective vaccine strategies to combat a variety of intracellular bacterial pathogens. This proposal is innovative because it provides a comprehensive approach to explore the relatively unknown signal integration between extra- and intracellular innate immune mechanisms following F. tularensis SchuS4 infection in our CDC-approved ABSL3/BSL3 facility. This study will identify the F. tularensis component(s) and the receptor(s) responsible for triggering the cytosolic machinery and elucidate the molecular mechanisms by which extra- and intracellular signals are integrated to elicit an optimal innate immune response. PUBLIC HEALTH RELEVANCE: This proposal aims to investigate the immunopathologic mechanisms underlying tularemia, a zoonotic disease caused by Francisella tularensis, a Category A biothreat agent. The studies will focus on exploring the cell biology of signal integration between key components of innate immunity and how these processes at the cellular level contribute to the host's ability to resist microbial challenge. Defining the molecular mechanism(s) of innate immunity will be an essential first step towards development of immunotherapeutic, as well as effective vaccine strategies to combat this fatal disease.
描述(申请人提供):表面表达的Toll样受体(TLRs)和一类新描述的胞质模式识别受体(PRRs),属于Nod样受体(NLR)家族成员,在对抗A类生物制剂--细胞内病原体Francisella tularensis的天然宿主防御中发挥重要作用。最近有研究表明,图拉氏疟原虫在免疫细胞中触发TLR2信号,这种PRR的突变与感染的易感性增加有关。同样,通过含有半胱氨酸天冬氨酸氨基转移酶招募结构域(ASC)的凋亡相关斑点样蛋白(ASC)、NLR接头分子和随后的caspase-1激活信号对于诱导对图拉氏丝虫病的保护性免疫是必不可少的。一个有趣的问题仍然没有答案是TLR和NLR信号通路之间的确切关系,以及响应F.tularensis的NLR的激活是发生在TLRs下游还是独立于TLR信号。此外,触发下游信号事件的图拉氏丝虫特异性成分(S)和NLR途径的受体(S)尚不清楚。本研究试图通过以下具体目的来解决这些问题:1)鉴定激活NLR途径的土拉氏杆菌SchuS4组分(S),并评价部分NLRs在介导对土拉F杆菌的促炎反应中的作用。2)建立了TLR2和NLR信号通路整合的关键部位。这项提议将研究先天免疫关键组成部分之间信号整合的细胞生物学,以及这些在细胞水平上的过程如何有助于宿主抵抗微生物挑战的能力。确定先天免疫的分子机制(S)将是发展免疫治疗以及有效的疫苗策略以对抗各种细胞内细菌病原体的必要的第一步。这一建议是创新的,因为它提供了一种综合的方法来探索在我们CDC批准的ABSL3/BSL3设施中感染图拉氏杆菌SchuS4后细胞外和细胞内天然免疫机制之间相对未知的信号整合。这项研究将确定负责触发胞液机制的图拉氏杆菌组分(S)和受体(S),并阐明整合细胞外和细胞内信号以诱导最佳先天免疫反应的分子机制。公共卫生相关性:这项提案旨在调查图拉热症的免疫病理机制,图拉热症是一种由A类生物制剂图拉氏菌引起的人畜共患病。这些研究将集中于探索先天免疫关键组成部分之间信号整合的细胞生物学,以及这些细胞水平上的过程如何有助于宿主抵抗微生物挑战的能力。确定先天免疫的分子机制(S)将是发展免疫治疗以及有效的疫苗策略对抗这种致命疾病的必要的第一步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Meenakshi Malik其他文献

Meenakshi Malik的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Meenakshi Malik', 18)}}的其他基金

Repression of inflammasome by Francisella tularensis
土拉弗朗西斯菌对炎症小体的抑制
  • 批准号:
    10046747
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Repression of inflammasome by Francisella tularensis
土拉弗朗西斯菌对炎症小体的抑制
  • 批准号:
    8574070
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Synergistic extra and intracellular recognition of F. tularensis
土拉弗朗西斯胞外和胞内的协同识别
  • 批准号:
    7589310
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Synergistic extra and intracellular recognition of F. tularensis
土拉弗朗西斯胞外和胞内的协同识别
  • 批准号:
    7749571
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了